Published in Eur Urol on July 20, 2012
Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol (2015) 2.20
Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml. PLoS One (2013) 1.09
Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer. Oncotarget (2014) 1.06
Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer. Curr Opin Urol (2016) 1.00
PCA3 and PCA3-based nomograms improve diagnostic accuracy in patients undergoing first prostate biopsy. Int J Mol Sci (2013) 0.90
The role of biomarkers in the assessment of prostate cancer risk prior to prostate biopsy: which markers matter and how should they be used? World J Urol (2014) 0.83
Prostate-specific antigen screening in prostate cancer: perspectives on the evidence. J Natl Cancer Inst (2014) 0.82
Nomograms for colorectal cancer: A systematic review. World J Gastroenterol (2015) 0.82
Evaluation of prostate cancer antigen 3 for detecting prostate cancer: a systematic review and meta-analysis. Sci Rep (2016) 0.79
Prostate cancer antigen 3 to select men for prostate biopsy: stop, go, or proceed with caution? Eur Urol (2012) 0.79
Urinary biomarkers for prostate cancer. Curr Opin Urol (2015) 0.78
Additional value of PCA3 density to predict initial prostate biopsy outcome. World J Urol (2014) 0.77
RNA biomarkers to facilitate the identification of aggressive prostate cancer. Mol Aspects Med (2015) 0.76
Function of PCA3 in prostate tissue and clinical research progress on developing a PCA3 score. Chin J Cancer Res (2014) 0.76
Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa). EJIFCC (2014) 0.75
Optimizing the clinical utility of PCA3 to diagnose prostate cancer in initial prostate biopsy. BMC Cancer (2015) 0.75
Long Non-Coding RNA as Potential Biomarker for Prostate Cancer: Is It Making a Difference? Int J Environ Res Public Health (2017) 0.75
Current Insights into Long Non-Coding RNAs (LncRNAs) in Prostate Cancer. Int J Mol Sci (2017) 0.75
Prediction of Low Birth Weight Delivery by Maternal Status and Its Validation: Decision Curve Analysis. Int J Prev Med (2017) 0.75
The role of prostate cancer biomarkers in undiagnosed men. Curr Opin Urol (2017) 0.75
Prostate transitional zone volume-based nomogram for predicting prostate cancer and high progression prostate cancer in a real-world population. J Cancer Res Clin Oncol (2017) 0.75
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Effect of dutasteride on the risk of prostate cancer. N Engl J Med (2010) 12.78
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA (2005) 8.72
EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol (2010) 8.21
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet (2009) 6.91
EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol (2013) 6.54
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med (2012) 5.49
Retracted Generation of pluripotent stem cells from adult human testis. Nature (2008) 5.49
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 5.44
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol (2011) 5.27
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA (2008) 5.25
Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst (2007) 4.85
Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. Eur Urol (2007) 4.67
Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol (2003) 4.66
Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a systematic review and cumulative analysis of comparative studies. Eur Urol (2009) 4.58
A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol (2007) 4.37
Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer. J Clin Virol (2008) 4.25
Association between two unlinked loci at 8q24 and prostate cancer risk among European Americans. J Natl Cancer Inst (2007) 4.24
African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? J Clin Oncol (2013) 4.20
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol (2010) 4.17
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA (2004) 4.10
Pelvic lymph node dissection in prostate cancer. Eur Urol (2009) 3.93
Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. Eur Urol (2008) 3.83
DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res (2002) 3.78
DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol (2003) 3.52
Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol (2008) 3.50
The use of polymer (Hem-o-lok) clips for management of the renal hilum during laparoscopic nephrectomy. Eur Urol (2006) 3.48
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov (2011) 3.43
Renal cell carcinoma guideline. Eur Urol (2007) 3.42
Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol (2011) 3.36
Impact of statin use on oncologic outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy. J Urol (2013) 3.35
Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group. Eur Urol (2013) 3.34
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA (2006) 3.32
Adjuvant radiotherapy for patients with locally advanced prostate cancer--a new standard? Eur Urol (2008) 3.27
Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. Eur Urol (2012) 3.26
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA (2007) 3.25
Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol (2003) 3.23
An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol (2004) 3.21
Stem cell characteristics in prostate cancer cell lines. Eur Urol (2009) 3.21
A non-cancer-related survival benefit is associated with partial nephrectomy. Eur Urol (2011) 3.18
Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol (2003) 3.17
Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis. Int J Urol (2012) 3.17
Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol (2005) 3.15
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet (2008) 3.14
Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol (2009) 3.14
Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer (2009) 3.12
Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol (2011) 3.10
Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell (2013) 3.08
The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients. Int J Radiat Oncol Biol Phys (2010) 3.06
Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol (2004) 3.06
Perioperative outcomes of robot-assisted radical prostatectomy compared with open radical prostatectomy: results from the nationwide inpatient sample. Eur Urol (2011) 3.03
Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer (2011) 3.02
The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol (2010) 3.02
Renal tumor biopsies for evaluation of small renal tumors: why, in whom, and how? Eur Urol (2008) 2.97
European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol (2013) 2.93
Extended 21-sample needle biopsy protocol for diagnosis of prostate cancer in 1000 consecutive patients. Eur Urol (2007) 2.92
ETS gene fusions in prostate cancer: from discovery to daily clinical practice. Eur Urol (2009) 2.91
Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. Eur Heart J (2006) 2.91
A 20-gene model for molecular nodal staging of bladder cancer: development and prospective assessment. Lancet Oncol (2011) 2.89
Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device. J Urol (2012) 2.89
Novel artificial neural network for early detection of prostate cancer. J Clin Oncol (2002) 2.88
External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Eur Urol (2008) 2.85
In vitro investigations of tissue-engineered multilayered urothelium established from bladder washings. Eur Urol (2008) 2.84
Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med (2010) 2.83
Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol (2007) 2.79
Extensive biopsies and transurethral prostate resection in men with previous negative biopsies and high or increasing prostate specific antigen. J Urol (2009) 2.77
Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol (2006) 2.77
An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int (2012) 2.77
Perioperative mortality is significantly greater in septuagenarian and octogenarian patients treated with radical cystectomy for urothelial carcinoma of the bladder. Urology (2011) 2.76
Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet (2002) 2.76
Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. Eur Urol (2009) 2.76
Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy. Eur Urol (2012) 2.74
Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol (2003) 2.72
Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series. Eur Urol (2008) 2.72
Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int (2013) 2.69
The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int (2011) 2.68
Retracted EPCA-2: a highly specific serum marker for prostate cancer. Urology (2007) 2.67
Pathological outcomes in men with low risk and very low risk prostate cancer: implications on the practice of active surveillance. J Urol (2013) 2.66
Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol (2007) 2.66